JOP20190190A1 - معالجة سرطان - Google Patents

معالجة سرطان

Info

Publication number
JOP20190190A1
JOP20190190A1 JOP/2019/0190A JOP20190190A JOP20190190A1 JO P20190190 A1 JOP20190190 A1 JO P20190190A1 JO P20190190 A JOP20190190 A JO P20190190A JO P20190190 A1 JOP20190190 A1 JO P20190190A1
Authority
JO
Jordan
Prior art keywords
cancer treatment
erdafitinib
span
dir
ltr
Prior art date
Application number
JOP/2019/0190A
Other languages
English (en)
Inventor
Arlene O Siefker-Radtke
Porre Peter Marie Z De
Kim Stuyckens
Anjali Narayan Avadhani
Yohann Loriot
Ruixo Juan Jose Perez
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61094531&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JOP20190190(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Priority claimed from PCT/EP2018/052694 external-priority patent/WO2018141921A1/en
Publication of JOP20190190A1 publication Critical patent/JOP20190190A1/ar
Application granted granted Critical
Publication of JOP20190190B1 publication Critical patent/JOP20190190B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Prostheses (AREA)
  • Medicinal Preparation (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Processing And Handling Of Plastics And Other Materials For Molding In General (AREA)
  • Laminated Bodies (AREA)

Abstract

يوفر الاختراع الحالي طريقة لمعالجة سرطان باستخدام الإردافيتنيب <span dir="LTR">erdafitinib</span>.
JOJO/P/2019/0190A 2017-02-06 2018-02-02 معالجة سرطان JOP20190190B1 (ar)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762455211P 2017-02-06 2017-02-06
EP17209098 2017-12-20
PCT/EP2018/052694 WO2018141921A1 (en) 2017-02-06 2018-02-02 Cancer treatment

Publications (2)

Publication Number Publication Date
JOP20190190A1 true JOP20190190A1 (ar) 2019-08-04
JOP20190190B1 JOP20190190B1 (ar) 2024-04-18

Family

ID=61094531

Family Applications (1)

Application Number Title Priority Date Filing Date
JOJO/P/2019/0190A JOP20190190B1 (ar) 2017-02-06 2018-02-02 معالجة سرطان

Country Status (26)

Country Link
US (2) US11077106B2 (ar)
EP (2) EP3576740B1 (ar)
JP (3) JP2020505425A (ar)
KR (2) KR20250069693A (ar)
CN (1) CN110198716A (ar)
AU (2) AU2018216969B2 (ar)
BR (1) BR112019016043A2 (ar)
CA (1) CA3049737A1 (ar)
DK (1) DK3576740T3 (ar)
ES (1) ES2953005T3 (ar)
FI (1) FI3576740T3 (ar)
HR (1) HRP20230697T1 (ar)
HU (1) HUE062453T2 (ar)
IL (1) IL268463A (ar)
JO (1) JOP20190190B1 (ar)
LT (1) LT3576740T (ar)
MX (2) MX2019009304A (ar)
NZ (2) NZ796822A (ar)
PH (1) PH12019501885A1 (ar)
PL (1) PL3576740T3 (ar)
RS (1) RS64778B1 (ar)
SG (2) SG10202105110VA (ar)
SI (1) SI3576740T1 (ar)
SM (1) SMT202300233T1 (ar)
TW (1) TWI874925B (ar)
UA (1) UA126336C2 (ar)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20170104A (es) 2014-09-26 2017-05-31 Janssen Pharmaceutica Nv Uso de paneles de genes mutantes de fgfr en la identificación de pacientes con cáncer que responderán al tratamiento con un inhibidor de fgfr
US20200208224A1 (en) * 2014-09-26 2020-07-02 Janssen Pharmaceutica Nv Use Of FGFR Mutant Gene Panels In Identifying Cancer Patients That Will Be Responsive To Treatment With An FGFR Inhibitor
HRP20230697T1 (hr) * 2017-02-06 2023-10-13 Janssen Pharmaceutica Nv Liječenje karcinoma
CN113423402A (zh) * 2019-02-12 2021-09-21 詹森药业有限公司 癌症治疗
EP3946340A1 (en) * 2019-03-29 2022-02-09 Janssen Pharmaceutica NV Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
CN113645974A (zh) * 2019-03-29 2021-11-12 詹森药业有限公司 用于治疗尿路上皮癌的fgfr酪氨酸激酶抑制剂
PH12022552093A1 (en) * 2020-02-12 2023-11-29 Janssen Pharmaceutica Nv Fgfr tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer
WO2021201201A1 (ja) * 2020-04-03 2021-10-07 インタープロテイン株式会社 新型コロナウイルス感染症（ｃｏｖｉｄ－１９）の予防または治療剤および医薬組成物
CN121263186A (zh) * 2023-05-24 2026-01-02 詹森药业有限公司 用厄达替尼治疗局部晚期或转移性尿路上皮癌

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3695B1 (ar) * 2015-02-10 2020-08-27 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n- (3.5- ثنائي ميثوكسي فينيل)-n-(1-ميثيل إيثيل)-n- 3-( ميثيل-h1-بيرازول-4-يل) كينوكسالين-6-يل) إيثان- 1.2-ثنائي الأمين)
US10478494B2 (en) * 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
HRP20230697T1 (hr) * 2017-02-06 2023-10-13 Janssen Pharmaceutica Nv Liječenje karcinoma

Also Published As

Publication number Publication date
HUE062453T2 (hu) 2023-11-28
EP3576740B1 (en) 2023-06-14
SG11201907199QA (en) 2019-09-27
JP2023022190A (ja) 2023-02-14
CN110198716A (zh) 2019-09-03
CA3049737A1 (en) 2018-08-09
KR20190110581A (ko) 2019-09-30
PH12019501885A1 (en) 2020-06-29
AU2024201871A1 (en) 2024-04-11
AU2024201871B2 (en) 2026-02-26
JP7668777B2 (ja) 2025-04-25
NZ755301A (en) 2025-12-19
US11077106B2 (en) 2021-08-03
FI3576740T3 (fi) 2023-08-31
AU2018216969A1 (en) 2019-07-25
MX2022007955A (es) 2022-07-27
US20220110935A1 (en) 2022-04-14
BR112019016043A2 (pt) 2020-03-31
AU2018216969B2 (en) 2024-04-11
SMT202300233T1 (it) 2023-09-06
RS64778B1 (sr) 2023-11-30
UA126336C2 (uk) 2022-09-21
PL3576740T3 (pl) 2023-09-11
JP2020505425A (ja) 2020-02-20
EP4286005A3 (en) 2024-03-06
EP3576740A1 (en) 2019-12-11
TWI874925B (zh) 2025-03-01
JOP20190190B1 (ar) 2024-04-18
JP2025024064A (ja) 2025-02-19
NZ796822A (en) 2025-12-19
TW202402290A (zh) 2024-01-16
HRP20230697T1 (hr) 2023-10-13
DK3576740T3 (da) 2023-07-24
ES2953005T3 (es) 2023-11-07
EP4286005A2 (en) 2023-12-06
IL268463A (en) 2019-09-26
SI3576740T1 (sl) 2023-10-30
SG10202105110VA (en) 2021-06-29
LT3576740T (lt) 2023-08-10
US20200022976A1 (en) 2020-01-23
KR20250069693A (ko) 2025-05-19
MX2019009304A (es) 2019-09-19

Similar Documents

Publication Publication Date Title
EA201992497A1 (ru) МОДУЛЯТОРЫ K-Ras
EA201990296A1 (ru) Антитела против siglec-7 для лечения рака
LT3986897T (lt) Egfr inhibitorius, skirtas vėžiui gydyti
EA201991818A1 (ru) Лечение рака
MX392368B (es) Composiciones y metodos para el tratamiento del cancer
NZ762505A (en) Antibody-pyrrolobenzodiazepine derivative conjugate
MX394380B (es) Compuestos dinucleótidos cíclicos para eltratamiento de cáncer
PH12019500095A1 (en) Compounds, compositions, and methods for the treatment of disease
JOP20190190B1 (ar) معالجة سرطان
HUE053191T2 (hu) 2-Heteroaril-3-oxo-2,3-dihidropiridazin-4-karboxamidok rák kezelésére
EA201692472A1 (ru) Соединения для лечения рака мозга
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
TN2019000211A1 (en) Antitumoral compounds
EA202191086A1 (ru) Комбинированная терапия меланомы
MY186711A (en) Igf-1r antibody-drug-conjugate and its use for the treatment of cancer
MX2020006297A (es) Variantes de cd19.
MX382904B (es) Combinaciones de fármacos para tratar mieloma múltiple.
EA202091881A1 (ru) Соединения для лечения боли
PH12018501455A1 (en) Therapeutic compostions and methods for treating hepatitis b
IL281845A (en) Combination therapy for the treatment of cancer
MX378739B (es) Compuestos de 2-oxindol.
MX2017016114A (es) Metodos para tratar o prevenir una proteopatia.
MX2018000694A (es) Tratamiento del prurito.
EA201691896A1 (ru) Соединения и способы их применения
JOP20210216A1 (ar) علاج السرطان